Has polivy's progression free survival rate improved in recent clinical trials?

Yes. There have been notable improvements in progression-free survival (PFS) with polatuzumab vedotin (Polivy) in recent trials, in both first-line and relapsed/refractory settings.

- First-line diffuse large B-cell lymphoma (DLBCL): POLARIX trial
- Design: Polatuzumab vedotin added to rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) vs standard R-CHOP.
- Outcome: PFS was significantly improved with pola-R-CHP compared with R-CHOP. Overall survival data were not yet mature at the initial analyses, so a clear OS advantage had not been established at that time. The safety profile was consistent with known effects of the drugs, with some higher rates of certain toxicities (e.g., neuropathy, cytopenias).

- Relapsed/refractory DLBCL: pola-BR combinations
- Several studies in later-line settings (e.g., polatuzumab vedotin with bendamustine and rituximab, vs bendamustine and rituximab alone) showed improved PFS and responses in eligible patients.
- These results supported the use of Polivy in combination regimens for relapsed/refractory disease and contributed to regulatory approvals in various regions.

If you’d like, I can pull exact numbers (hazard ratios, median PFS, confidence intervals) from the most recent publications or conference presentations and tailor the answer to a specific setting (first-line vs relapsed/refractory) or a particular trial. Would you like that?